HTG Molecular Diagnostics Company Profile (NASDAQ:HTGM)

About HTG Molecular Diagnostics (NASDAQ:HTGM)

HTG Molecular Diagnostics logoHTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company's HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company's HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:HTGM
  • CUSIP: N/A
  • Web: www.htgmolecular.com
Capitalization:
  • Market Cap: $35.43 million
  • Outstanding Shares: 9,525,000
Average Prices:
  • 50 Day Moving Avg: $4.73
  • 200 Day Moving Avg: $3.13
  • 52 Week Range: $1.20 - $13.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.16
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.64 million
  • Price / Sales: 6.28
  • Book Value: ($1.36) per share
  • Price / Book: -2.74
Profitability:
  • EBIDTA: ($21,680,000.00)
  • Net Margins: -532.94%
  • Return on Equity: -356.46%
  • Return on Assets: -77.79%
Debt:
  • Debt-to-Equity Ratio: -3.12%
  • Current Ratio: 1.99%
  • Quick Ratio: 1.80%
Misc:
  • Average Volume: 3.44 million shs.
  • Beta: 0.29
  • Short Ratio: 0.27
 

Frequently Asked Questions for HTG Molecular Diagnostics (NASDAQ:HTGM)

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) released its quarterly earnings data on Monday, May, 15th. The company reported ($0.73) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $0.15. The business had revenue of $1.37 million for the quarter, compared to analysts' expectations of $2.44 million. HTG Molecular Diagnostics had a negative net margin of 532.94% and a negative return on equity of 356.46%. View HTG Molecular Diagnostics' Earnings History.

Where is HTG Molecular Diagnostics' stock going? Where will HTG Molecular Diagnostics' stock price be in 2017?

3 analysts have issued 1 year price targets for HTG Molecular Diagnostics' shares. Their predictions range from $5.00 to $6.50. On average, they expect HTG Molecular Diagnostics' share price to reach $5.83 in the next twelve months. View Analyst Ratings for HTG Molecular Diagnostics.

Are investors shorting HTG Molecular Diagnostics?

HTG Molecular Diagnostics saw a decrease in short interest in May. As of May 15th, there was short interest totalling 644,244 shares, a decrease of 47.4% from the April 28th total of 1,223,925 shares. Based on an average trading volume of 580,101 shares, the short-interest ratio is presently 1.1 days. Currently, 15.9% of the shares of the stock are sold short.

Who are some of HTG Molecular Diagnostics' key competitors?

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the folowing people:

  • Ann F. Hanham Ph.D., Chairman of the Board
  • Timothy B. Johnson, President, Chief Executive Officer, Director
  • Shaun D. McMeans, Vice President of Finance and Administration, Chief Financial Officer
  • Patrick C. Roche Ph.D., Senior Vice President - Research and Product Development
  • Suzanne Hill, Vice President of North American Capital Sales
  • Debra A. Gordon Ph.D., J.D., Vice President and Chief Legal Counsel
  • John L. Lubniewski, Chief Business Officer
  • Donnie M. Hardison, Director
  • Harry A. George, Independent Director
  • Mary Hoult, Independent Director

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who owns HTG Molecular Diagnostics stock?

HTG Molecular Diagnostics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include NOVO A (15.90%), GLAXOSMITHKLINE PLC (9.80%), FMR LLC (8.36%), Vanguard Group Inc. (1.21%), Granahan Investment Management Inc. MA (0.41%) and Two Sigma Securities LLC (0.27%). Company insiders that own HTG Molecular Diagnostics stock include Debra A Gordon, John L Lubniewski, Patrick C Roche, Plc Glaxosmithkline, Shaun D Mcmeans and Tim B Johnson. View Institutional Ownership Trends for HTG Molecular Diagnostics.

Who bought HTG Molecular Diagnostics stock? Who is buying HTG Molecular Diagnostics stock?

HTG Molecular Diagnostics' stock was purchased by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Vanguard Group Inc., Two Sigma Securities LLC and UBS Group AG. Company insiders that have bought HTG Molecular Diagnostics stock in the last two years include Debra A Gordon, John L Lubniewski and Patrick C Roche. View Insider Buying and Selling for HTG Molecular Diagnostics.

How do I buy HTG Molecular Diagnostics stock?

Shares of HTG Molecular Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is HTG Molecular Diagnostics' stock price today?

One share of HTG Molecular Diagnostics stock can currently be purchased for approximately $3.72.


MarketBeat Community Rating for HTG Molecular Diagnostics (NASDAQ HTGM)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  77
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for HTG Molecular Diagnostics (NASDAQ:HTGM) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $5.83 (56.81% upside)

Analysts' Ratings History for HTG Molecular Diagnostics (NASDAQ:HTGM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017Rodman & RenshawBoost Price TargetBuy -> Buy$4.50 -> $6.00HighView Rating Details
4/19/2017Canaccord GenuityBoost Price TargetHold$5.50 -> $6.50LowView Rating Details
10/13/2016HC WainwrightReiterated RatingBuy$5.00N/AView Rating Details
3/28/2016Leerink SwannReiterated RatingOutperform$10.00 -> $5.00N/AView Rating Details
6/3/2015JMP SecuritiesInitiated CoverageOutperform$21.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for HTG Molecular Diagnostics (NASDAQ:HTGM)
Earnings by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)
Earnings History by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1($0.58)($0.73)$2.44 million$1.37 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.87)($0.92)$2.05 million$0.91 millionViewListenView Earnings Details
8/9/2016Q2($0.95)($0.98)$1.90 millionViewListenView Earnings Details
5/12/2016Q1($0.83)($1.02)$1.23 million$0.87 millionViewListenView Earnings Details
3/24/2016Q4($0.79)($0.83)$1.31 million$1.22 millionViewListenView Earnings Details
11/12/2015Q315($0.85)($0.76)$1.07 million$1.00 millionViewListenView Earnings Details
8/6/2015Q215($0.71)($1.73)$1.01 million$0.79 millionViewListenView Earnings Details
6/1/2015Q115($14.99)$1.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for HTG Molecular Diagnostics (NASDAQ:HTGM)
Current Year EPS Consensus Estimate: $-2.25 EPS
Next Year EPS Consensus Estimate: $-1.72 EPS

Dividends

Dividend History for HTG Molecular Diagnostics (NASDAQ:HTGM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for HTG Molecular Diagnostics (NASDAQ:HTGM)
Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 47.31%
Insider Trades by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)
Institutional Ownership by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)
Insider Trades by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/27/2017Plc GlaxosmithklineInsiderSell300,000$10.15$3,045,000.00View SEC Filing  
4/4/2016Debra A GordonVPSell1,672$2.89$4,832.08View SEC Filing  
4/4/2016John L LubniewskiInsiderSell796$2.89$2,300.44View SEC Filing  
4/4/2016Shaun D McmeansCFOSell1,601$2.89$4,626.89View SEC Filing  
4/4/2016Tim B JohnsonCEOSell4,914$2.89$14,201.46View SEC Filing  
3/14/2016Debra A GordonVPSell5,535$2.38$13,173.30View SEC Filing  
3/14/2016John L LubniewskiInsiderSell6,889$2.38$16,395.82View SEC Filing  
3/14/2016Patrick C RocheSVPSell5,929$2.38$14,111.02View SEC Filing  
3/14/2016Shaun D McmeansCFOSell5,651$2.38$13,449.38View SEC Filing  
3/14/2016Tim B JohnsonCEOSell10,621$2.38$25,277.98View SEC Filing  
3/9/2016Debra A GordonVPSell3,256$2.69$8,758.64View SEC Filing  
3/9/2016John L LubniewskiInsiderSell4,067$2.69$10,940.23View SEC Filing  
3/9/2016Patrick C RocheSVPSell3,491$2.69$9,390.79View SEC Filing  
3/9/2016Shaun D McmeansCFOSell3,325$2.69$8,944.25View SEC Filing  
3/9/2016Tim B JohnsonCEOSell6,299$2.69$16,944.31View SEC Filing  
8/24/2015Debra A GordonVPBuy1,000$5.16$5,160.00View SEC Filing  
8/18/2015Patrick C. RocheSVPBuy6,500$5.76$37,440.00View SEC Filing  
8/11/2015John L LubniewskiInsiderBuy5,000$7.67$38,350.00View SEC Filing  
5/11/2015A/S NovoMajor ShareholderBuy365,106$14.00$5,111,484.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for HTG Molecular Diagnostics (NASDAQ:HTGM)
Latest Headlines for HTG Molecular Diagnostics (NASDAQ:HTGM)
Source:
DateHeadline
americanbankingnews.com logoHTG Molecular Diagnostics Inc (HTGM) Sees Significant Decline in Short Interest
www.americanbankingnews.com - May 28 at 8:44 AM
finance.yahoo.com logoHTG Molecular Diagnostics, Inc. :HTGM-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
finance.yahoo.com - May 19 at 5:30 PM
americanbankingnews.com logoHTG Molecular Diagnostics Inc (HTGM) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 16 at 11:58 PM
finance.yahoo.com logoETFs with exposure to HTG Molecular Diagnostics, Inc. : May 16, 2017
finance.yahoo.com - May 16 at 5:40 PM
finance.yahoo.com logoEdited Transcript of HTGM earnings conference call or presentation 15-May-17 8:30pm GMT
finance.yahoo.com - May 16 at 5:40 PM
bizjournals.com logoResearch Reports Initiation on Medical Laboratories Stocks -- Cancer Genetics, Exact Sciences, HTG Molecular Diagnostics, and BioTelemetry
www.bizjournals.com - May 16 at 11:18 AM
seekingalpha.com logoHTG Molecular Diagnostics' (HTGM) CEO TJ Johnson on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 16 at 11:18 AM
americanbankingnews.com logoHTG Molecular Diagnostics Inc (HTGM) Posts Earnings Results
www.americanbankingnews.com - May 16 at 10:54 AM
americanbankingnews.com logoHTG Molecular Diagnostics Inc (HTGM) Price Target Raised to $6.00 at Rodman & Renshaw
www.americanbankingnews.com - May 16 at 8:12 AM
reuters.com logoBRIEF-HTG Molecular Q1 loss per share $0.73
www.reuters.com - May 15 at 5:17 PM
finance.yahoo.com logoInvestor Network: HTG Molecular Diagnostics, Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 5:17 PM
finance.yahoo.com logoHTG Molecular Diagnostics Reports First Quarter 2017 Results
finance.yahoo.com - May 15 at 5:17 PM
americanbankingnews.com logoHTG Molecular Diagnostics Inc (HTGM) Sees Large Drop in Short Interest
www.americanbankingnews.com - May 13 at 8:44 AM
americanbankingnews.com logoHTG Molecular Diagnostics Inc (HTGM) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 12 at 12:06 AM
streetinsider.com logoHTG Molecular Diagnostics (HTGM) Says HTG EdgeSeq PATH Assay to Launch in Second Quarter - StreetInsider.com
www.streetinsider.com - May 4 at 12:27 PM
finance.yahoo.com logoHTG Molecular Diagnostics Introduces HTG EdgeSeq PATH Assay to Launch in Second Quarter 2017
finance.yahoo.com - May 4 at 12:27 PM
finance.yahoo.com logoETFs with exposure to HTG Molecular Diagnostics, Inc. : May 1, 2017
finance.yahoo.com - May 1 at 6:31 PM
finance.yahoo.com logoHTG Molecular Diagnostics to Hold 2017 First Quarter Results Conference Call on May 15, 2017
finance.yahoo.com - May 1 at 6:31 PM
americanbankingnews.com logoHTG Molecular Diagnostics (HTGM) Receives Coverage Optimism Rating of 0.26
www.americanbankingnews.com - April 30 at 3:05 PM
americanbankingnews.com logoHTG Molecular Diagnostics (HTGM) Earning Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 25 at 8:15 PM
globenewswire.com logoHTG Molecular Diagnostics and Instituto Valenciano de Oncología Initiate Breast Cancer Recurrence Risk Collaboration - GlobeNewswire (press release)
globenewswire.com - April 24 at 8:06 AM
finance.yahoo.com logoHTG Molecular Diagnostics and Instituto Valenciano de Oncología Initiate Breast Cancer Recurrence Risk Collaboration
finance.yahoo.com - April 24 at 8:05 AM
americanbankingnews.com logoHTG Molecular Diagnostics' (HTGM) "Hold" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - April 19 at 11:57 PM
finance.yahoo.com logoETFs with exposure to HTG Molecular Diagnostics, Inc. : April 17, 2017
finance.yahoo.com - April 17 at 5:11 PM
finance.yahoo.com logoHTG Molecular Diagnostics Transfers Listing to The Nasdaq Capital Market
finance.yahoo.com - April 17 at 5:11 PM
reuters.com logoBRIEF-HTG Molecular Diagnostics, Centre Léon Bérard enter molecular profiling research agreement
www.reuters.com - April 17 at 10:59 AM
seekingalpha.com logoHTG Molecular Diagnostics inks master services agreement with Daiichi Sankyo; shares ahead 24% premarket
seekingalpha.com - April 17 at 10:59 AM
streetinsider.com logoHTG Molecular Diagnostics (HTGM) Announces Molecular Profiling Research Agreement with Centre Leon Berard
www.streetinsider.com - April 17 at 10:59 AM
finance.yahoo.com logoHTG Molecular Diagnostics and Daiichi Sankyo Complete Master Services Agreement
finance.yahoo.com - April 17 at 10:59 AM
finance.yahoo.com logoHTG Molecular Diagnostics and Centre Léon Bérard Enter Into Molecular Profiling Research Agreement
finance.yahoo.com - April 17 at 10:59 AM
americanbankingnews.com logoHTG Molecular Diagnostics (HTGM) Getting Somewhat Positive Media Coverage, Report Finds
www.americanbankingnews.com - April 16 at 1:25 PM
americanbankingnews.com logoHTG Molecular Diagnostics Inc (HTGM) Short Interest Update
www.americanbankingnews.com - April 15 at 7:02 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: TearLab and HTG Molecular Diagnostics
finance.yahoo.com - April 7 at 10:20 AM
finance.yahoo.com logoETFs with exposure to HTG Molecular Diagnostics, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 10:20 AM
americanbankingnews.com logoAnalysts Expect HTG Molecular Diagnostics Inc (HTGM) to Announce ($0.63) Earnings Per Share
www.americanbankingnews.com - April 4 at 12:43 AM
americanbankingnews.com logoHTG Molecular Diagnostics Inc (HTGM) Insider Sells $3,045,000.00 in Stock
www.americanbankingnews.com - March 29 at 7:20 PM
finance.yahoo.com logoHTG MOLECULAR DIAGNOSTICS, INC Financials
finance.yahoo.com - March 29 at 6:16 PM
streetinsider.com logoHTG Molecular Diagnostics (HTGM) Files to Offer $75M in Common Stock
www.streetinsider.com - March 28 at 10:25 PM
biz.yahoo.com logoHTG MOLECULAR DIAGNOSTICS, INC Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - March 28 at 11:22 AM
rttnews.com logoHTG Molecular Diagnostics (HTGM) Soared To A New High For The Year
www.rttnews.com - March 27 at 11:09 AM
us.rd.yahoo.com logoEdited Transcript of HTGM earnings conference call or presentation 23-Mar-17 9:00pm GMT
us.rd.yahoo.com - March 24 at 5:51 PM
wsj.com logoHTG Molecular's Shares Soar 450% the Past Two Days
blogs.wsj.com - March 24 at 5:51 PM
finance.yahoo.com logoAdvances in Healthcare Technology and Osteoarthritis Drug Therapies Propel Two Healthcare Stocks
finance.yahoo.com - March 24 at 9:55 AM
seekingalpha.com logoHTG Molecular Diagnostics' (HTGM) CEO TJ Johnson on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 23 at 11:20 PM
investopedia.com logoHTG Cancer Diagnostic Test Gets CE Mark (HTGM)
www.investopedia.com - March 23 at 11:20 PM
biz.yahoo.com logoQ4 2016 HTG Molecular Diagnostics Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 23 at 11:20 PM
marketwatch.com logoHTG Molecular's stock soars again after CE mark obtained for assay used in lung tumor analysis
us.rd.yahoo.com - March 23 at 11:20 PM
us.rd.yahoo.com logoHow a Key European Decision Is Making All the Difference at HTG
us.rd.yahoo.com - March 23 at 11:20 PM
us.rd.yahoo.com logoHTG Molecular Cancer Diagnostic Test Gets CE Mark
us.rd.yahoo.com - March 23 at 11:20 PM
us.rd.yahoo.com logoHTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN GeneReader NGS System
us.rd.yahoo.com - March 23 at 11:20 PM

Social

Chart

HTG Molecular Diagnostics (HTGM) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff